JP2020502252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502252A5 JP2020502252A5 JP2019534721A JP2019534721A JP2020502252A5 JP 2020502252 A5 JP2020502252 A5 JP 2020502252A5 JP 2019534721 A JP2019534721 A JP 2019534721A JP 2019534721 A JP2019534721 A JP 2019534721A JP 2020502252 A5 JP2020502252 A5 JP 2020502252A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- pyridine
- pyridin
- quinoline
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 29
- 229910052799 carbon Inorganic materials 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 20
- -1 C 6 -halo alkyne Chemical class 0.000 claims 16
- 125000005842 heteroatom Chemical group 0.000 claims 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 10
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- 150000001721 carbon Chemical group 0.000 claims 8
- 125000004122 cyclic group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000004434 sulfur atom Chemical group 0.000 claims 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- CGWOEOXQHIMZEQ-UHFFFAOYSA-N 3-[1-[[4-(2-phenylquinolin-3-yl)phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound OC1=NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1C1=CC2=CC=CC=C2N=C1C1=CC=CC=C1 CGWOEOXQHIMZEQ-UHFFFAOYSA-N 0.000 claims 2
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- BZQNGAOLGDUCQF-JOCHJYFZSA-N (3R)-1-[6-[5-[(benzylamino)methyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]-8-fluoroquinolin-4-yl]piperidin-3-amine Chemical compound C(C1=CC=CC=C1)NCC=1C=C2C(=NC=1)NC=C2C=1C=C2C(=CC=NC2=C(C=1)F)N1C[C@@H](CCC1)N BZQNGAOLGDUCQF-JOCHJYFZSA-N 0.000 claims 1
- YJCXYZMWVUGXRW-HNNXBMFYSA-N (3S)-1-[6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinolin-4-yl]piperidin-3-amine Chemical compound N1C=C(C=2C1=NC=CC=2)C=1C=C2C(=CC=NC2=CC=1)N1C[C@H](CCC1)N YJCXYZMWVUGXRW-HNNXBMFYSA-N 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 1
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 claims 1
- KPXJTZIQXSWGIT-UHFFFAOYSA-N 1-[4-[[3-amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinolin-4-yl]amino]piperidin-1-yl]ethanone Chemical compound NC=1C=NC2=CC=C(C=C2C=1NC1CCN(CC1)C(C)=O)C1=CNC2=NC=CC=C21 KPXJTZIQXSWGIT-UHFFFAOYSA-N 0.000 claims 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- XWIFBFUJGAWXHS-UHFFFAOYSA-N 3-(4-chloroquinolin-6-yl)-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound ClC1=CC=NC2=CC=C(C=C12)C1=CNC2=NC=C(C=C21)C(=O)NC XWIFBFUJGAWXHS-UHFFFAOYSA-N 0.000 claims 1
- KHNUNRTYYWJLRW-UHFFFAOYSA-N 3-(4-chloroquinolin-6-yl)-N-methyl-N-prop-2-enyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound ClC1=CC=NC2=CC=C(C=C12)C1=CNC2=NC=C(C=C21)C(=O)N(CC=C)C KHNUNRTYYWJLRW-UHFFFAOYSA-N 0.000 claims 1
- PAMXGACATZRENQ-UHFFFAOYSA-N 3-(8-chloroquinolin-6-yl)-N-methyl-N-prop-2-enyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound ClC=1C=C(C=C2C=CC=NC=12)C1=CNC2=NC=C(C=C21)C(=O)N(CC=C)C PAMXGACATZRENQ-UHFFFAOYSA-N 0.000 claims 1
- XLCGSUWTGKAGTE-UHFFFAOYSA-N 3-(8-fluoro-4-pyridin-3-ylquinolin-6-yl)-N-(pyridin-3-ylmethyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound FC=1C=C(C=C2C(=CC=NC=12)C=1C=NC=CC=1)C1=CNC2=NC=C(C=C21)C(=O)NCC=1C=NC=CC=1 XLCGSUWTGKAGTE-UHFFFAOYSA-N 0.000 claims 1
- GTDNEGKWGVJGLX-UHFFFAOYSA-N 3-(8-fluoro-4-pyridin-3-ylquinolin-6-yl)-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound FC=1C=C(C=C2C(=CC=NC=12)C=1C=NC=CC=1)C1=CNC2=NC=C(C=C21)C(=O)NC GTDNEGKWGVJGLX-UHFFFAOYSA-N 0.000 claims 1
- LVZGZIQMEWQNDY-UHFFFAOYSA-N 3-(8-fluoroquinolin-6-yl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound FC=1C=C(C=C2C=CC=NC=12)C1=CNC2=NC=C(C=C21)C(=O)N LVZGZIQMEWQNDY-UHFFFAOYSA-N 0.000 claims 1
- DXKFAZQYMJDRSE-UHFFFAOYSA-N 3-(8-fluoroquinolin-6-yl)-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound FC=1C=C(C=C2C=CC=NC=12)C1=CNC2=NC=C(C=C21)C(=O)NC DXKFAZQYMJDRSE-UHFFFAOYSA-N 0.000 claims 1
- CJXCXSPUKJXTHK-UHFFFAOYSA-N 3-(8-fluoroquinolin-6-yl)-N-methyl-N-prop-2-enyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound FC=1C=C(C=C2C=CC=NC=12)C1=CNC2=NC=C(C=C21)C(=O)N(CC=C)C CJXCXSPUKJXTHK-UHFFFAOYSA-N 0.000 claims 1
- JADLORYTDWUCHF-UHFFFAOYSA-N 3-(8-methoxyquinolin-6-yl)-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound COC=1C=C(C=C2C=CC=NC=12)C1=CNC2=NC=C(C=C21)C(=O)NC JADLORYTDWUCHF-UHFFFAOYSA-N 0.000 claims 1
- WTZMAWLFZDCCGZ-UHFFFAOYSA-N 3-[3-(oxan-4-ylmethylamino)quinolin-6-yl]-N-(pyridin-3-ylmethyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound O1CCC(CC1)CNC=1C=NC2=CC=C(C=C2C=1)C1=CNC2=NC=C(C=C21)C(=O)NCC=1C=NC=CC=1 WTZMAWLFZDCCGZ-UHFFFAOYSA-N 0.000 claims 1
- LHSFFGVPEQSDGZ-RSAXXLAASA-N 3-[3-amino-4-[(3S)-3-aminopiperidin-1-yl]quinolin-6-yl]-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrochloride Chemical compound Cl.CNC(=O)c1cnc2[nH]cc(-c3ccc4ncc(N)c(N5CCC[C@H](N)C5)c4c3)c2c1 LHSFFGVPEQSDGZ-RSAXXLAASA-N 0.000 claims 1
- ZEJZYNWWSBPCNF-FSRHSHDFSA-N 3-[4-[(3R)-3-aminopiperidin-1-yl]-8-fluoroquinolin-6-yl]-N-(pyrimidin-5-ylmethyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrochloride Chemical compound Cl.N[C@@H]1CCCN(C1)c1ccnc2c(F)cc(cc12)-c1c[nH]c2ncc(cc12)C(=O)NCc1cncnc1 ZEJZYNWWSBPCNF-FSRHSHDFSA-N 0.000 claims 1
- VSRGWSJHBZSEHJ-FTBISJDPSA-N 3-[4-[(3S)-3-aminopiperidin-1-yl]-3-[(3-chlorophenyl)methylamino]quinolin-6-yl]-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrochloride Chemical compound Cl.CNC(=O)c1cnc2[nH]cc(-c3ccc4ncc(NCc5cccc(Cl)c5)c(N5CCC[C@H](N)C5)c4c3)c2c1 VSRGWSJHBZSEHJ-FTBISJDPSA-N 0.000 claims 1
- HZLFXUUVVAHBBX-RSAXXLAASA-N 3-[4-[(3S)-3-aminopiperidin-1-yl]-3-nitroquinolin-6-yl]-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrochloride Chemical compound Cl.CNC(=O)c1cnc2[nH]cc(-c3ccc4ncc(c(N5CCC[C@H](N)C5)c4c3)[N+]([O-])=O)c2c1 HZLFXUUVVAHBBX-RSAXXLAASA-N 0.000 claims 1
- HTRWKFBTQABGLJ-UHFFFAOYSA-N 3-[4-[(4-aminocyclohexyl)amino]-3-nitroquinolin-6-yl]-N-(pyridin-3-ylmethyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrochloride Chemical compound Cl.NC1CCC(CC1)Nc1c(cnc2ccc(cc12)-c1c[nH]c2ncc(cc12)C(=O)NCc1cccnc1)[N+]([O-])=O HTRWKFBTQABGLJ-UHFFFAOYSA-N 0.000 claims 1
- IQGRKLZSRNFPGE-UHFFFAOYSA-N 3-[8-fluoro-4-(2-phenylethyl)quinolin-6-yl]-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound FC=1C=C(C=C2C(=CC=NC=12)CCC1=CC=CC=C1)C1=CNC2=NC=C(C=C21)C(=O)NC IQGRKLZSRNFPGE-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- DCEQQTFFVRJVHP-UHFFFAOYSA-N 4-chloro-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinoline Chemical compound ClC1=CC=NC2=CC=C(C=C12)C1=CNC2=NC=CC=C21 DCEQQTFFVRJVHP-UHFFFAOYSA-N 0.000 claims 1
- LTRCPJPJRDKLHD-UHFFFAOYSA-N 4-pyridin-3-yl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinoline Chemical compound N1=CC(=CC=C1)C1=CC=NC2=CC=C(C=C12)C1=CNC2=NC=CC=C21 LTRCPJPJRDKLHD-UHFFFAOYSA-N 0.000 claims 1
- YFWJRQZPTNUYSM-UHFFFAOYSA-N 6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinoline Chemical compound N1C=C(C=2C1=NC=CC=2)C=1C=C2C=CC=NC2=CC=1 YFWJRQZPTNUYSM-UHFFFAOYSA-N 0.000 claims 1
- OAJJRWPTDSPUPV-UHFFFAOYSA-N 8-fluoro-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinoline Chemical compound FC=1C=C(C=C2C=CC=NC=12)C1=CNC2=NC=CC=C21 OAJJRWPTDSPUPV-UHFFFAOYSA-N 0.000 claims 1
- SYCSBDPYAXPTKW-UHFFFAOYSA-N 8-methoxy-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinoline Chemical compound COC=1C=C(C=C2C=CC=NC=12)C1=CNC2=NC=CC=C21 SYCSBDPYAXPTKW-UHFFFAOYSA-N 0.000 claims 1
- BIWUFINUXCARFC-UHFFFAOYSA-N 8-methyl-4-phenyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinoline Chemical compound CC=1C=C(C=C2C(=CC=NC=12)C1=CC=CC=C1)C1=CNC2=NC=CC=C21 BIWUFINUXCARFC-UHFFFAOYSA-N 0.000 claims 1
- WCGVAQKYQAEAIH-UHFFFAOYSA-N 8-methyl-4-pyridin-3-yl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinoline Chemical compound CC=1C=C(C=C2C(=CC=NC=12)C=1C=NC=CC=1)C1=CNC2=NC=CC=C21 WCGVAQKYQAEAIH-UHFFFAOYSA-N 0.000 claims 1
- CLPPRTBPZGASGR-UHFFFAOYSA-N 8-methyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinoline hydrochloride Chemical compound Cl.Cc1cc(cc2cccnc12)-c1c[nH]c2ncccc12 CLPPRTBPZGASGR-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 claims 1
- 102100033363 Dual specificity tyrosine-phosphorylation-regulated kinase 1B Human genes 0.000 claims 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 claims 1
- 101000926738 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1B Proteins 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- KHQYSWUSDRSLMP-UHFFFAOYSA-N N-(1-methylpiperidin-4-yl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinolin-4-amine Chemical compound CN1CCC(CC1)NC1=CC=NC2=CC=C(C=C12)C1=CNC2=NC=CC=C21 KHQYSWUSDRSLMP-UHFFFAOYSA-N 0.000 claims 1
- XEUXZQDACQNEDS-UHFFFAOYSA-N N-(3-aminopropyl)-3-(8-chloroquinolin-6-yl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrochloride Chemical compound Cl.NCCCNC(=O)c1cnc2[nH]cc(-c3cc(Cl)c4ncccc4c3)c2c1 XEUXZQDACQNEDS-UHFFFAOYSA-N 0.000 claims 1
- IEYDHHFHEKZAMM-UHFFFAOYSA-N N-(3-aminopropyl)-3-(8-fluoro-4-pyridin-3-ylquinolin-6-yl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrochloride Chemical compound Cl.NCCCNC(=O)c1cnc2[nH]cc(-c3cc(F)c4nccc(-c5cccnc5)c4c3)c2c1 IEYDHHFHEKZAMM-UHFFFAOYSA-N 0.000 claims 1
- XKYCTSHCXRBBDN-UHFFFAOYSA-N N-(3-aminopropyl)-3-(8-fluoroquinolin-6-yl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrochloride Chemical compound Cl.NCCCNC(=O)c1cnc2[nH]cc(-c3cc(F)c4ncccc4c3)c2c1 XKYCTSHCXRBBDN-UHFFFAOYSA-N 0.000 claims 1
- XZZQNHGVXUUUJJ-UHFFFAOYSA-N N-[3-(8-fluoro-4-pyridin-3-ylquinolin-6-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]acetamide Chemical compound FC=1C=C(C=C2C(=CC=NC=12)C=1C=NC=CC=1)C1=CNC2=NC=C(C=C21)NC(C)=O XZZQNHGVXUUUJJ-UHFFFAOYSA-N 0.000 claims 1
- RYTRXGFGSSHDBX-UHFFFAOYSA-N N-benzyl-3-(8-chloroquinolin-6-yl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound C(C1=CC=CC=C1)NC(=O)C=1C=C2C(=NC=1)NC=C2C=1C=C2C=CC=NC2=C(C=1)Cl RYTRXGFGSSHDBX-UHFFFAOYSA-N 0.000 claims 1
- UDZZFGIWCOHTOH-UHFFFAOYSA-N N-benzyl-3-(8-fluoroquinolin-6-yl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound C(C1=CC=CC=C1)NC(=O)C=1C=C2C(=NC=1)NC=C2C=1C=C2C=CC=NC2=C(C=1)F UDZZFGIWCOHTOH-UHFFFAOYSA-N 0.000 claims 1
- BKAFJYQDXGZTKS-UHFFFAOYSA-N N-methyl-3-(4-pyridin-3-ylquinolin-6-yl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound CNC(=O)C=1C=C2C(=NC=1)NC=C2C=1C=C2C(=CC=NC2=CC=1)C=1C=NC=CC=1 BKAFJYQDXGZTKS-UHFFFAOYSA-N 0.000 claims 1
- UYKPAASBLHVCBO-UHFFFAOYSA-N N-methyl-3-quinolin-6-yl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound CNC(=O)C=1C=C2C(=NC=1)NC=C2C=1C=C2C=CC=NC2=CC=1 UYKPAASBLHVCBO-UHFFFAOYSA-N 0.000 claims 1
- ORBNLRQBHQLUIW-UHFFFAOYSA-N N-methyl-N-(1-methylpiperidin-4-yl)-3-nitro-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinolin-4-amine Chemical compound CN(C1=C(C=NC2=CC=C(C=C12)C1=CNC2=NC=CC=C21)[N+](=O)[O-])C1CCN(CC1)C ORBNLRQBHQLUIW-UHFFFAOYSA-N 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000000232 haloalkynyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- NGXSWUFDCSEIOO-UHFFFAOYSA-N pyrrolidin-3-amine Chemical compound NC1CCNC1 NGXSWUFDCSEIOO-UHFFFAOYSA-N 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022133200A JP2022166286A (ja) | 2016-12-23 | 2022-08-24 | Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16460096 | 2016-12-23 | ||
| EP16460096.7 | 2016-12-23 | ||
| PCT/US2017/067527 WO2018119039A1 (en) | 2016-12-23 | 2017-12-20 | Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022133200A Division JP2022166286A (ja) | 2016-12-23 | 2022-08-24 | Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502252A JP2020502252A (ja) | 2020-01-23 |
| JP2020502252A5 true JP2020502252A5 (cg-RX-API-DMAC7.html) | 2021-01-28 |
| JP7134973B2 JP7134973B2 (ja) | 2022-09-12 |
Family
ID=57777491
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534721A Active JP7134973B2 (ja) | 2016-12-23 | 2017-12-20 | Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体 |
| JP2022133200A Pending JP2022166286A (ja) | 2016-12-23 | 2022-08-24 | Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022133200A Pending JP2022166286A (ja) | 2016-12-23 | 2022-08-24 | Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10577365B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3558321B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7134973B2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3558321T (cg-RX-API-DMAC7.html) |
| PL (1) | PL3558321T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018119039A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3558321T (lt) * | 2016-12-23 | 2023-05-10 | Felicitex Therapeutics, Inc. | Chinolinų dariniai kaip dyrk1a ir (arba) dyrk1b kinazių inhibitoriai |
| CN110483508B (zh) * | 2019-08-29 | 2020-05-08 | 山东大学 | 化合物、制备方法及在制备GSK-3β抑制剂中的应用 |
| JP2022552019A (ja) | 2019-10-18 | 2022-12-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 病的血管障害の治療のための作用物質としての３－フェニルスルホニル－キノリン誘導体 |
| KR20230003981A (ko) * | 2021-06-30 | 2023-01-06 | 한국화학연구원 | DYRK1 억제제인 피롤로[3,2-c]피리딘 유도체 및 이의 용도 |
| EP4415817A1 (en) * | 2021-10-12 | 2024-08-21 | BioSplice Therapeutics, Inc. | 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors |
| WO2025069008A1 (en) | 2023-09-28 | 2025-04-03 | Graviton Bioscience Bv | Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors |
| CN120904163A (zh) * | 2025-10-09 | 2025-11-07 | 北京大学第一医院(北京大学第一临床医学院) | 一种喹啉类化合物或其药学上可接受的盐及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1490364B1 (en) | 2002-03-28 | 2007-09-26 | Eisai R&D Management Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
| US20070066641A1 (en) | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
| GB0405055D0 (en) | 2004-03-05 | 2004-04-07 | Eisai London Res Lab Ltd | JNK inhibitors |
| PL2332940T3 (pl) * | 2004-03-30 | 2013-03-29 | Vertex Pharma | Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych |
| EP1828180A4 (en) | 2004-12-08 | 2010-09-15 | Glaxosmithkline Llc | 1H-pyrrolo [2,3-BETA] PYRIDINE |
| CN101541783B (zh) * | 2006-06-30 | 2014-10-01 | 苏尼西斯制药有限公司 | 吡啶酮基pdk1抑制剂 |
| US8552019B2 (en) * | 2008-12-05 | 2013-10-08 | Merck Sharp & Dohme Corp. | Inhibitors of phosphoinositide dependent kinase 1 (PDK1) |
| WO2011149950A2 (en) | 2010-05-24 | 2011-12-01 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
| CN103153063B (zh) | 2010-07-30 | 2016-02-17 | 肿瘤疗法科学股份有限公司 | 喹啉衍生物及含有其的melk抑制剂 |
| US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
| AU2012230890A1 (en) | 2011-03-22 | 2013-09-26 | Amgen Inc. | Azole compounds as Pim inhibitors |
| BR112014000115A2 (pt) | 2011-07-05 | 2016-10-04 | Vertex Pharma | processos e intermediários para a produção de azaindóis, e suas formas sólidas |
| KR102006749B1 (ko) | 2011-08-19 | 2019-08-02 | 디악쏘니 | Dyrk1 억제제 및 이의 용도 |
| WO2014085795A1 (en) | 2012-11-30 | 2014-06-05 | University Of Rochester | Mixed lineage kinase inhibitors for hiv/aids therapies |
| CN105777756B (zh) | 2014-07-02 | 2019-03-01 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| LT3558321T (lt) * | 2016-12-23 | 2023-05-10 | Felicitex Therapeutics, Inc. | Chinolinų dariniai kaip dyrk1a ir (arba) dyrk1b kinazių inhibitoriai |
-
2017
- 2017-12-20 LT LTEPPCT/US2017/067527T patent/LT3558321T/lt unknown
- 2017-12-20 WO PCT/US2017/067527 patent/WO2018119039A1/en not_active Ceased
- 2017-12-20 JP JP2019534721A patent/JP7134973B2/ja active Active
- 2017-12-20 US US15/848,786 patent/US10577365B2/en active Active
- 2017-12-20 EP EP17883520.3A patent/EP3558321B1/en active Active
- 2017-12-20 EP EP22214338.0A patent/EP4183786A1/en not_active Withdrawn
- 2017-12-20 PL PL17883520.3T patent/PL3558321T3/pl unknown
-
2022
- 2022-08-24 JP JP2022133200A patent/JP2022166286A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502252A5 (cg-RX-API-DMAC7.html) | ||
| AU2004289672B2 (en) | Inhibition of FGFR3 and treatment of multiple myeloma | |
| US7825132B2 (en) | Inhibition of FGFR3 and treatment of multiple myeloma | |
| US9108963B2 (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| AU2003288899B2 (en) | Benzimidazole quinolinones and uses thereof | |
| KR101506044B1 (ko) | Ｃ―ｆｍｓ 및/또는 ｃ―ｋｉｔ 활성 조절 화합물 및 이들의 용도 | |
| TWI730959B (zh) | 作為激酶抑制劑之雜環醯胺 | |
| JP2016164184A5 (cg-RX-API-DMAC7.html) | ||
| JP2012525431A5 (cg-RX-API-DMAC7.html) | ||
| JP2005508313A5 (cg-RX-API-DMAC7.html) | ||
| PE20070004A1 (es) | Imidazoquinolinas como inhibidores de quinasa de lipido | |
| JP2009529047A5 (cg-RX-API-DMAC7.html) | ||
| MX2012009381A (es) | Metodos y sistema para retirar componentes del gas a partir de los gases de proceso. | |
| CA3124102C (en) | Novel hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | |
| EP2477629A1 (en) | Substituted heteroarylamide analogs as mglur5 negative allosteric modulators and methods of making and using the same | |
| JP2011510985A5 (cg-RX-API-DMAC7.html) | ||
| JP2017504652A5 (cg-RX-API-DMAC7.html) | ||
| JP2020502252A (ja) | Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体 | |
| JP2019537581A5 (cg-RX-API-DMAC7.html) | ||
| JP2012526772A5 (cg-RX-API-DMAC7.html) | ||
| JP2019512534A5 (cg-RX-API-DMAC7.html) | ||
| RU2018143284A (ru) | Некоторые ингибиторы протеинкиназы | |
| AU2015212495A1 (en) | Antibacterial combinations comprising polymyxin | |
| JP2009510162A5 (cg-RX-API-DMAC7.html) | ||
| CN1976706B (zh) | 抑制fgfr3及治疗多发性骨髓瘤 |